GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sam-A-Pharm Co Ltd (XKRX:009300) » Definitions » Price-to-Owner-Earnings

Sam-A-Pharm Co (XKRX:009300) Price-to-Owner-Earnings : 2.87 (As of Dec. 11, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Sam-A-Pharm Co Price-to-Owner-Earnings?

As of today (2024-12-11), Sam-A-Pharm Co's share price is ₩17030.00. Sam-A-Pharm Co's Owner Earnings per Share (TTM) ended in Sep. 2024 was ₩5927.72. It's Price-to-Owner-Earnings for today is 2.87.


The historical rank and industry rank for Sam-A-Pharm Co's Price-to-Owner-Earnings or its related term are showing as below:

XKRX:009300' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.66   Med: 10.97   Max: 92.06
Current: 2.8

During the past 13 years, the highest Price-to-Owner-Earnings of Sam-A-Pharm Co was 92.06. The lowest was 2.66. And the median was 10.97.


XKRX:009300's Price-to-Owner-Earnings is ranked better than
97.45% of 431 companies
in the Drug Manufacturers industry
Industry Median: 26.62 vs XKRX:009300: 2.80

As of today (2024-12-11), Sam-A-Pharm Co's share price is ₩17030.00. Sam-A-Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ₩3,731.00. Therefore, Sam-A-Pharm Co's PE Ratio (TTM) for today is 4.56.

As of today (2024-12-11), Sam-A-Pharm Co's share price is ₩17030.00. Sam-A-Pharm Co's EPS without NRI for the trailing twelve months (TTM) ended in was ₩3,731.00. Therefore, Sam-A-Pharm Co's PE Ratio without NRI for today is 4.56.

During the past 13 years, Sam-A-Pharm Co's highest PE Ratio without NRI was 581.67. The lowest was 3.98. And the median was 12.77.


Sam-A-Pharm Co Price-to-Owner-Earnings Historical Data

The historical data trend for Sam-A-Pharm Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sam-A-Pharm Co Price-to-Owner-Earnings Chart

Sam-A-Pharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.36 89.10 12.38 5.02 3.55

Sam-A-Pharm Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.98 3.55 2.80 3.81 3.58

Competitive Comparison of Sam-A-Pharm Co's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Sam-A-Pharm Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sam-A-Pharm Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sam-A-Pharm Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sam-A-Pharm Co's Price-to-Owner-Earnings falls into.



Sam-A-Pharm Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sam-A-Pharm Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=17030.00/5927.72
=2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sam-A-Pharm Co  (XKRX:009300) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sam-A-Pharm Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Sam-A-Pharm Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Sam-A-Pharm Co Business Description

Traded in Other Exchanges
N/A
Address
265 Ojeon-Dong, Uiwang-Si, KOR, 437-832
Sam-A-Pharm Co Ltd is a South Korea based company engages in the manufacturing of pharmaceutical products. Its products include medicines for cold and fever, inflammatory, allergy, nutrition, and respiratory and digestive systems.

Sam-A-Pharm Co Headlines

No Headlines